Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 21, 2018--The “Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 8, 29, 9, 1, 42, 6 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.
Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Graft Versus Host Disease (GVHD) - Overview Graft Versus Host Disease (GVHD) - Therapeutics Development Graft Versus Host Disease (GVHD) - Therapeutics Assessment Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development Graft Versus Host Disease (GVHD) - Drug Profiles Graft Versus Host Disease (GVHD) - Dormant Projects Graft Versus Host Disease (GVHD) - Discontinued Products Graft Versus Host Disease (GVHD) - Product Development Milestones Appendix
Companies MentionedAbbVie Inc AbGenomics International Inc Amgen Inc Biogen Inc Bristol-Myers Squibb Co Capricor Therapeutics Inc Cell2B Advanced Therapeutics SA Cellect Biotechnology Ltd Cellective BioTherapy Inc CSL Ltd F. Hoffmann-La Roche Ltd Fate Therapeutics Inc Generon (Shanghai) Corp Ltd GlaxoSmithKline Plc Incyte Corp Inspyr Therapeutics Inc Jazz Pharmaceuticals Plc Johnson & Johnson Kadmon Corp LLC Kamada Ltd Kiadis Pharma NV Kymab Ltd LG Chem Ltd Millennium Pharmaceuticals Inc Novartis AG OncoImmune Inc Pfizer Inc Pharmicell Co Ltd Pluristem Therapeutics Inc REGiMMUNE Corp Sanofi Visterra Inc Xenikos BV XL-protein GmbH Zai Lab Ltd For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rj576z/graft_versus_host?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180921005558/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Immunosuppressive Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/21/2018 03:28 PM/DISC: 09/21/2018 03:28 PM